{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:16:23Z","timestamp":1790140583165,"version":"4.0.1"},"reference-count":107,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Servier International"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.2217\/fon-2022-1286","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:08:05Z","timestamp":1683886085000},"page":"789-810","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"first","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology & Stem Cell Transplantation,Hannover Medical School,\rCarl-Neuberg-Str. 1,\r30625,\rHannover,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-2366","authenticated-orcid":false,"given":"C\u00e9dric","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Servier International,\r92284,\rSuresnes,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-8301","authenticated-orcid":false,"given":"Ole","family":"Hauch","sequence":"additional","affiliation":[{"name":"Hauch Consultancy,\r1060,\rBrussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0191-8265","authenticated-orcid":false,"given":"Olga M","family":"Klibanov","sequence":"additional","affiliation":[{"name":"IQVIA, Medical and Patient Communications,\rParsippany, NJ07054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-3922","authenticated-orcid":false,"given":"Tanushree","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"IQVIA, Real World Evidence,\rGurugram,\rHaryana12002, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7546-0007","authenticated-orcid":false,"given":"Vincent","family":"Rives","sequence":"additional","affiliation":[{"name":"Servier International,\r92284,\rSuresnes,\rFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0178"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"e_1_3_6_6_1","unstructured":"Cancer.net . Leukemia - Acute Myeloid - AML: statistics. www.cancer.net\/cancer-types\/leukemia-acute-myeloid-aml\/statistics (Accessed August 23 2022)."},{"key":"e_1_3_6_7_1","unstructured":"The Economist Intelligence Unit . Acute Myeloid leukemia: mapping the policy response to an acute cancer in France Germany Italy Spain and the UK. https:\/\/worldcancerinitiative.economist.com\/pdf\/acute-myeloid-leukemia\/acute-myeloid-leukemia-report.pdf (Accessed 23August2022)."},{"key":"e_1_3_6_8_1","unstructured":"National Comprehensive Cancer Network (NCCN) . NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia version 2.2022-June 14 2022. www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf (Accessed 23August2022)."},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.018"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0032-2"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066100"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.216"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.303"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62105-8"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.7525"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2714"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2020.21.3.721"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074306"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-250878"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.275"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253070"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0903840"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-5"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.6899"},{"key":"e_1_3_6_26_1","unstructured":"European Medicines Agency . Public summary of opinion on orphan designation: ivosidenib for the treatment of acute myeloid leukemia. www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/16\/1802-public-summary-opinion-orphan-designation-ivosidenib-treatment-acute-myeloid-leukemia_en.pdf (Accessed 23August2022)."},{"key":"e_1_3_6_27_1","unstructured":"PR Newswire . Servier submits a marketing authorization application to the European Medicines Agency (EMA) for TIBSOVO\u00ae (ivosidenib tablets) for patients with IDH1-mutated acute myeloid leukemia (AML) and cholangiocarcinoma. www.prnewswire.com\/news-releases\/servier-submits-a-marketing-authorization-application-to-the-european-medicines-agency-ema-for-tibsovo-ivosidenib-tablets-for-patients-with-idh1-mutated-acute-myeloid-leukemia-aml-and-cholangiocarcinoma-301500159.html (Accessed August 23 2022)."},{"key":"e_1_3_6_28_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)","author":"Higgins JPT","year":"2022","unstructured":"Higgins JPT , ThomasJ, ChandlerJet al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane (2022)."},{"key":"e_1_3_6_29_1","unstructured":"Centre for Reviews and Dissemination University of York . Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf (Accessed 24August2022)."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_3_6_31_1","unstructured":"National Institute for Health and Care Excellence . Single technology appraisal and highly specialised technologies evaluation: user guide for company evidence submission template. www.nice.org.uk\/process\/pmg24\/chapter\/clinical-effectiveness#quality-assessment-of-the-relevant-clinical-effectiveness-evidence (Accessed 24August2022)."},{"key":"e_1_3_6_32_1","unstructured":"Github . WebPlotDigitizer. https:\/\/apps.automeris.io\/wpd\/ (Accessed 12September2022)."},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28113"},{"key":"e_1_3_6_34_1","unstructured":"EU Clinical Trials Register . A multicenter open randomized controlled phase IIb trial evaluating efficacy and tolerability of GRASPA (L-asparaginase encapsulated in red blood cells eryaspase) plus low-dose cytarabine versus low-dosecytarabine alone in treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients unfit forintensive chemotherapy. ENFORCE 1 study. www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-002026-78\/results (Accessed 25August2022)."},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.38"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-496596"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147802"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00494-0"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560557"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000617"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198093"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33828"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01053"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.172353"},{"issue":"3","key":"e_1_3_6_50_1","first-page":"415","article-title":"Low-dose cytarabine versus best supportive care for patients with acute myeloid leukemia unfit for the standard of care: egyptian centre experience","volume":"12","author":"Mohammed AA","year":"2021","unstructured":"Mohammed AA , ElsayedFM. Low-dose cytarabine versus best supportive care for patients with acute myeloid leukemia unfit for the standard of care: egyptian centre experience. Middle East J. Cancer12(3), 415\u2013421 (2021).","journal-title":"Middle East J. Cancer"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147805"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0773-5"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127253"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066613"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33403"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145379"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122896"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000561796.30124.a4"},{"key":"e_1_3_6_60_1","unstructured":"ClinicalTrials.gov . SGI-110 in adults with untreated acute myeloid leukemia (AML) not considered candidates for intensive remission induction. www.clinicaltrials.gov\/ct2\/show\/NCT02348489 (Accessed 25August2022)."},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.619.619"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S64067"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102458"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146468"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147601"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0257-z"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.951845"},{"issue":"1","key":"e_1_3_6_68_1","first-page":"225","article-title":"Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: bright AML 1003 final report and 4-year overall survival (OS) follow-up","volume":"4","author":"Heuser M","year":"2020","unstructured":"Heuser M , RobakT, MontesinosPet al. Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: bright AML 1003 final report and 4-year overall survival (OS) follow-up. Hemasphere4(Suppl. 1), 225 (2020).","journal-title":"Hemasphere"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04465-4"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129614"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04132-x"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140664"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-69"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.111"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134832"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3803-6"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7010"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33072"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.09.007"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0238-9"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000559300.20719.08"},{"issue":"1","key":"e_1_3_6_82_1","first-page":"273","article-title":"Effect of early blood counts on response and overall survival following glasdegib plus LDAC in newly diagnosed AML: Bright AML 1003 post hoc analysis","volume":"4","author":"Wang ES","year":"2020","unstructured":"Wang ES , HeuserM, SekeresMAet al. Effect of early blood counts on response and overall survival following glasdegib plus LDAC in newly diagnosed AML: Bright AML 1003 post hoc analysis. Hemasphere4(Suppl. 1), 273 (2020).","journal-title":"Hemasphere"},{"issue":"2","key":"e_1_3_6_83_1","first-page":"179","article-title":"Cytopenia management in the phase 3 Viale-C study of venetoclax plus low-dose cytarabine for patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy","volume":"5","author":"Wei AH","year":"2021","unstructured":"Wei AH , PanayiotidisP, MontesinosPet al. Cytopenia management in the phase 3 Viale-C study of venetoclax plus low-dose cytarabine for patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy. Hemasphere5(Suppl. 2), 179 (2021).","journal-title":"Hemasphere"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00555-8"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25062"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab112"},{"key":"e_1_3_6_87_1","article-title":"Comparative results of azacitidine and decitabine from a large prospective phase 3 study in treatment naive patients with acute myeloid leukemia not eligible for intensive chemotherapy","author":"Zeidan AM","year":"2020","unstructured":"Zeidan AM , FenauxP, GobbMet al. Comparative results of azacitidine and decitabine from a large prospective phase 3 study in treatment naive patients with acute myeloid leukemia not eligible for intensive chemotherapy. 62nd ASH Annual Meeting and Exposition (2020).","journal-title":"62nd ASH Annual Meeting and Exposition"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124034"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134850"},{"key":"e_1_3_6_90_1","unstructured":"EU Clinical Trials Register . A randomized study of tipifarnib versus best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in subjects 70 years or older. www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-001719-77\/results (Accessed 7September2022)."},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.116"},{"key":"e_1_3_6_92_1","unstructured":"ClinicalTrials.gov . An efficacy and safety study of decitabine (DACOGEN) plus talacotuzumab (JNJ-56022473; Anti CD123) versus decitabine (DACOGEN) alone in participants with acute myeloid Leukemia (AML) ineligible for intensive chemotherapy. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02472145?term=An+Efficacy+and+Safety+Study+of+Decitabine+%28DACOGEN%29+Plus+Talacotuzumab+%28JNJ-56022473%3B+Anti+CD123%29+Versus+Decitabine+%28DACOGEN%29+Alone+in+Participants+With+Acute+Myeloid&draw=2&rank=1 (Accessed 23September2022)."},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30132-7"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01217"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197905103001902"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3467"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236992"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.267"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112304"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21860"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002140"},{"issue":"4","key":"e_1_3_6_106_1","first-page":"409","article-title":"Recent advances of targeted therapy in relapsed\/refractory acute myeloid leukemia","volume":"21","author":"Ma J","year":"2021","unstructured":"Ma J , GeZ. Recent advances of targeted therapy in relapsed\/refractory acute myeloid leukemia. Bosn. J. Basic Med. Sci.21(4), 409\u2013421 (2021).","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0842"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S187409"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205075"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-1286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:33Z","timestamp":1719125073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-1286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":107,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.2217\/fon-2022-1286"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-1286","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}